Mackenzie Financial Corp Sells 2,646 Shares of Amgen Inc. (NASDAQ:AMGN)

Mackenzie Financial Corp lessened its position in Amgen Inc. (NASDAQ:AMGN) by 1.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 167,192 shares of the medical research company’s stock after selling 2,646 shares during the quarter. Mackenzie Financial Corp’s holdings in Amgen were worth $43,577,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the company. Centricity Wealth Management LLC acquired a new stake in Amgen in the 4th quarter worth $25,000. Pinney & Scofield Inc. bought a new position in shares of Amgen during the 4th quarter worth about $26,000. Ritter Daniher Financial Advisory LLC DE increased its holdings in shares of Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company’s stock worth $33,000 after purchasing an additional 51 shares during the period. Synergy Investment Management LLC bought a new position in shares of Amgen during the 4th quarter worth about $34,000. Finally, Atala Financial Inc bought a new position in shares of Amgen during the 4th quarter worth about $34,000. Institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Morgan Stanley restated an “equal weight” rating on shares of Amgen in a report on Friday, May 2nd. Wells Fargo & Company restated an “equal weight” rating on shares of Amgen in a report on Wednesday, February 5th. Bank of America boosted their price objective on shares of Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a report on Wednesday, March 5th. Piper Sandler dropped their price objective on shares of Amgen from $329.00 to $328.00 and set an “overweight” rating on the stock in a report on Friday, May 16th. Finally, Royal Bank of Canada dropped their price objective on shares of Amgen from $324.00 to $320.00 and set an “outperform” rating on the stock in a report on Friday, May 2nd. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $309.22.

Amgen Price Performance

NASDAQ:AMGN opened at $271.66 on Monday. The firm has a market cap of $146.07 billion, a PE ratio of 35.98, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The company’s 50-day moving average price is $286.82 and its two-hundred day moving average price is $286.23.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating analysts’ consensus estimates of $4.18 by $0.72. The firm had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the business earned $3.96 earnings per share. On average, equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.50%. Amgen’s dividend payout ratio (DPR) is presently 86.86%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.